(Q37956403)

25 August 2017

title

Pharmacological considerations for the proper clinical use of aminoglycosides (English)

1 reference

25 August 2017

1 reference

5

Matthew E Falagas

1 reference

25 August 2017

Spyridon Pagkalis

1

1 reference

25 August 2017

Elpis Mantadakis

series ordinal

2

1 reference

25 August 2017

Michael N Mavros

series ordinal

3

1 reference

25 August 2017

Christina Ammari

series ordinal

4

1 reference

25 August 2017

publication date

1 December 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

17

1 reference

25 August 2017

page(s)

2277-2294

1 reference

Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Aminoglycoside induced ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Do we still need the aminoglycosides?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Potential of old-generation antibiotics to address current need for new antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

In-vitro evaluation of ampicillin/brobactam and comparison with other β-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Modelling time-kill studies to discern the pharmacodynamics of meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacodynamics of tobramycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Suboptimal aminoglycoside dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacokinetics and pharmacodynamics of antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Circadian variation in serum amikacin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Chronokinetic study of netilmicin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Tobramycin population pharmacokinetics in neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Pharmacodynamic effects of subinhibitory antibiotic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Cell wall alterations of gram-negative bacteria by aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Enhanced phagocytosis of encapsulated Escherichia coli strains after exposure to sub-MICs of antibiotics is correlated to changes of the bacterial cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

The influence of subminimal inhibitory concentrations of netilmicin and ceftriaxone on the interaction of Escherichia coli with host defences.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated beta-(1->3)-glucans, which bind aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

A three-dimensional computer model of four hypothetical mechanisms protecting biofilms from antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Distribution, organization, and ecology of bacteria in chronic wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Extended-interval aminoglycoside administration for children: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Aminoglycoside antibiotics induce bacterial biofilm formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Role of persisters and small-colony variants in antibiotic resistance of planktonic and biofilm-associated Staphylococcus aureus: an in vitro study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Autoradiography of gentamicin uptake by the rat proximal tubule cell

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Aminoglycoside dosages and nephrotoxicity: quantitative relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Endocytosis of aminoglycoside antibiotics in sensory hair cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Competitive antagonism of fluorescent gentamicin uptake in the cochlea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Response of mechanosensory hair cells of the zebrafish lateral line to aminoglycosides reveals distinct cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Combination drugs, an emerging option for antibacterial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

The neglected intrinsic resistome of bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Targeting a bacterial stress response to enhance antibiotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Synthesis and spectrum of the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Megalin Deficiency Offers Protection from Renal Aminoglycoside Accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

A role for sigma factor B in the emergence of Staphylococcus aureus small-colony variants and elevated biofilm production resulting from an exposure to aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597020-000000000-00000

Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability

21 January 2018

1 reference

12 December 2020

Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient

1 reference

12 December 2020

Aminoglycosides: nephrotoxicity

1 reference

12 December 2020

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

1 reference

12 December 2020

Postantibiotic suppression of bacterial growth

1 reference

12 December 2020

Dopamine, dobutamine, and dopexamine. A comparison of renal effects in unanesthetized human volunteers.

1 reference

12 December 2020

Treatment of osteomyelitis by liposomal gentamicin-impregnated calcium sulfate

1 reference

12 December 2020

Microsomal protein synthesis inhibition: an early manifestation of gentamicin nephrotoxicity

1 reference

12 December 2020

Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model

1 reference

12 December 2020

Glomerular hyperfiltration and albuminuria in critically ill patients

1 reference

12 December 2020

Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect

1 reference

12 December 2020

Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method

1 reference

12 December 2020

Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease

1 reference

12 December 2020

Killing and regrowth of bacteria in vitro: a review.

1 reference

12 December 2020

Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro

1 reference

12 December 2020

Renal functional reserve in humans

1 reference

12 December 2020

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients

1 reference

12 December 2020

[Ototoxicity of aminosides: recent results on uptake and clearance of gentamycin by sensory cells of the cochlea]

1 reference

12 December 2020

Factors affecting gentamicin pharmacokinetics in septic patients

1 reference

12 December 2020

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

1 reference

12 December 2020

[The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus].

1 reference

12 December 2020

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

1 reference

12 December 2020

In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.

1 reference

12 December 2020

Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes

1 reference

12 December 2020

Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic

1 reference

12 December 2020

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis

1 reference

12 December 2020

Duration and clinical relevance of postantibiotic effect in relation to the dosing interval

1 reference

12 December 2020

Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum

1 reference

12 December 2020

Aminoglycoside volume of distribution and illness severity in critically ill septic patients

1 reference

12 December 2020

Postantibiotic effects

1 reference

12 December 2020

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998

1 reference

12 December 2020

Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time

1 reference

12 December 2020

Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model

1 reference

12 December 2020

The role of fluid sequestration in the pathogenesis of mediastinitis

1 reference

12 December 2020

Population pharmacokinetics of amikacin in patients with haematological malignancies

1 reference

12 December 2020

Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group

1 reference

12 December 2020

Influence of ascites on tobramycin pharmacokinetics

1 reference

12 December 2020

Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis

1 reference

12 December 2020

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

1 reference

12 December 2020

Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside

1 reference

12 December 2020

Evidence for systematic temporal variation in 24-hour urinary creatinine excretion

1 reference

12 December 2020

National survey of extended-interval aminoglycoside dosing

1 reference

12 December 2020

Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition

1 reference

12 December 2020

Renal mitochondrial integrity during continuous gentamicin treatment

1 reference

12 December 2020

Back to the future: using aminoglycosides again and how to dose them optimally

1 reference

12 December 2020

10.2165/11597020-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1052350644

0 references

1 reference